Bharat Book Bureau
Dear Colleague,
The pipeline of therapeutic antibodies has been growing steadily, building on successful clinical trials, particularly in cancer. This growth will certainly accelerate as genomic companies with many novel targets seek to employ antibodies to modulate these targets. In addition, studies employing antibodies, or antibody mimics, are being ramped up as part of the explosive growth of proteomics. All of these trends place a tremendous emphasis on the development of new approaches for faster antibody development, improved methods of selection and optimization, alternatives for production, and evaluation for novel applications. As one of the fastest growing segments of the pharma market, the value of therapeutic antibodies is expected to more than triple in value. The success of current marketed products has led to escalation in antibody development, with more than 370 programs currently in the pipeline. Evolutions in innovation and business model dynamics will drive the sector’s dominant position. This conference will provide key updates on important developments in each of these areas. Recombinant Antibodies Conference will provide a forum for leading industry experts from major pharmaceutical companies to discuss and evaluate the latest challenges and problems facing the therapeutic antibodies market. The emerging field of antibody engineering will serve as the definitive source for researchers and engineers in biology and medicine, biochemistry, immunology, and molecular biology, as well as anyone who is interested in biotechnology and antibody engineering.
By attending the conference you will hear the very latest developments in the field of antibody therapy development:
Identify novel antigens and target validation
Implement breakthrough research in antibody engineering for enhanced
effector functions
Increase antibody safety
Conduct a competitive analysis on develop and optimising effector functions
Learn best practice strategies for agonistic and antagonistic antibodies
Discover the do’s and don’ts of immunotoxins
Acquire information on expanding indications for antibody therapy through improved delivery
Discover recent antibody developments in various therapeutic areas including oncology, infectious diseases, inflammatory diseases, CNS
Conduct a competitive analysis on results of long term therapy using antibodies
Get tips on monitoring results from the clinic through biomarkers for antibody efficiency
Get up-to-date knowledge on modern strategies to antibodies in targeting and imaging
I look forward to meeting you at the conference
Best regards
Nazmine T Mughal PhD
Conference Producer
Pharmaceutical Division
------------------------------------------------------------
Who should attend?
Senior Principal Scientist/Project Director, Project Leader, Senior Principle Scientist, Chief Scientific Officer, Chief Medical Officer, Manager, Senior Director, Chief Operating Officer, Senior Vice President, Chief Scientific Officer, Executive Director, Chief Executive Officer, Vice President of Project Management, Director, Discovery, Vice President of Technology, Patent Attorney
Workshop format
The purpose of the workshop is to allow delegates to engage in knowledge sharing with their peers in a smaller, less formal environment than the main conference.As such the audience size will typically be no more than 20 participants in order to enable maximum interaction between the workshop leader and delegates. The format is also more interactive, with less emphasis on ‘lecture-style’
Workshop agenda
Advances in the elucidation of immune regulatory mechanisms have allowed the development of novel immunomodulatory therapies utilising recombinant monoclonal antibodies. The topics in this workshop will include a review of some of the antibodies in development or approved for immunomodulatory therapy, the challenges and issues surrounding preclinical testing, and the problems in extrapolating preclinical data to clinical trials in man.
For more information kindly visit: http://www.bharatbook.com/
Photo:
http://www.prlog.org/
